Rationale: Serum chitinases may be novel biomarkers of airway inflammation and remodeling, but less is known about factors regulating their levels.
To realize the concept of precision medicine in patients with severe airway inflammation, who are notoriously difficult to treat, there is a great need for novel biomarkers of this disease. A relatively unexpected group of proteins has been proposed to show potential for this purpose-the chitinases.
Chitin is an abundant, tough structural polysaccharide used by a variety of organisms, including insects, crustaceans, parasites, fungi, and bacteria, to protect against external threats (1) . Although in humans chitin seems absent, enzymes capable of its degradation are expressed. The chitinase family includes the true chitinases-acidic mammalian chitinase (AMCase) and chitotriosidase-as well as the structurally related chitinase-like protein YKL-40, which lacks enzymatic activity (2) . In recent years, these proteins have been linked to airway inflammation (2) . Although AMCase has been associated with airway inflammation predominantly in animal models (3), chitotriosidase activity is increased in the airways of smokers and subjects with chronic obstructive pulmonary disease (COPD) compared with healthy control subjects (4, 5) , as well as in the serum of patients with asthma (6) . YKL-40 levels are increased in the serum and lungs of patients with asthma compared with healthy control subjects, and they correlate with markers of disease severity (7, 8) .
However, information is still lacking regarding the suitability of these proteins as biomarkers of airway inflammation. It was therefore our aim in this study to provide a more detailed evaluation of serum chitinase levels in airway disease by investigating both serum YKL-40 levels and chitotriosidase activity in parallel in patients taking part in the European multicenter BIOAIR (Longitudinal Assessment of Clinical Course and Biomarkers in Severe Chronic Airway Disease) study (9) (10) (11) . The design of this study enabled us, for the first time, to examine in the same study the repeatability of chitinase measurements over a 1-year period, the effect of oral steroid treatment, and the effect of spontaneous exacerbations in both patients with asthma and patients with COPD. YKL-40 levels and chitotriosidase activity are subject to genetic regulation and were therefore also analyzed, taking into account the effect of common polymorphisms in the CHI3L1 and CHIT1 genes, respectively. CHI3L1 rs4950928 (2131C.G) has been associated with features of asthma and increased serum YKL-40 (8, 12) , and individuals homozygous for a relatively common 24-bp duplication in exon 10 of CHIT1 (rs3831317) display a complete lack of chitotriosidase activity (13) . To assess whether acute airway obstruction and inflammation affect chitinase levels in blood or sputum, we also examined the effect of inhaled allergen on YKL-40 levels in two separate subsets of patients with mild atopic asthma following high-dose or repeated lowdose allergen challenge. Some of the results of these studies have been reported previously in the form of abstracts (14) (15) (16) .
Methods
Subjects BIOAIR cohort. BIOAIR is a European multicenter study (9) (10) (11) . Briefly, subjects were between 18 and 80 years of age and were divided into three groups: patients with mild to moderate asthma, patients with severe asthma, and patients with COPD (Table 1) . Further details and definitions regarding the BIOAIR study and patient groups are provided in the online supplement. To examine the repeatability of biomarker measurements, patients attended up to six scheduled clinic visits over the 1-year study period. Patients who had exacerbations had additional visits. Most patients taking part in the BIOAIR study (88% of all subjects) underwent a 2-week, double-blind, placebo-controlled oral steroid intervention consisting of a standard course of prednisolone (0.5 mg/kg body weight/d) added to regular treatment. For certain comparisons, a positive response to therapy was defined as an increase in FEV 1 greater than 12% following steroid treatment.
Healthy subjects. Baseline chitinase measurements were obtained from a group of up to 72 healthy volunteers aged 21-77 years (average age, 40 yr) recruited at the Academic Medical Center, University of Amsterdam, who have been examined in previous studies of chitinase levels (17) .
Allergen-challenged subjects with asthma. Plasma and sputum samples were collected from well-characterized patients with mild atopic asthma taking part in two separate allergen challenge studies (see online supplement for details). Patients underwent either (1) high-dose allergen challenge (n = 16) to produce a 20% acute fall in FEV 1 (18) or (2) repeated low-dose allergen challenge (n = 15) leading to minimal bronchoconstriction but eosinophilic airway inflammation and increased bronchial hyperresponsiveness to methacholine (19) .
Clinical Measurements
Lung function measurements, reversibility testing, fraction of exhaled nitric oxide (FE NO ) measurements, skin prick testing, and sputum induction and processing were all performed as described in the online supplement. Serum periostin levels were measured by ELISA using two rat antihuman periostin monoclonal antibodies (clones SS18A and SS17B) as described previously (20) .
YKL-40 assay. Serum YKL-40 levels were measured by ELISA according to the manufacturer's instructions (Human Chitinase 3-like 1 DuoSet ELISA Development Kit; R&D Systems, Abingdon, UK). Two different dilutions were made for each sample, from which an average was obtained. All samples were analyzed in duplicate in random order. Within-assay variability was 3%, and between-assay variability was 14%.
Chitotriosidase assay. Chitotriosidase activity in the serum was detected fluorometrically using the substrate 4-methylumbelliferyl-(4-deoxy)chitobiose as described elsewhere (21, 22) and as outlined in more detail in the online supplement. To discriminate between chitotriosidase activity and that of AMCase in serum samples, a neutralizing antibody against AMCase was used.
At a Glance Commentary
Scientific Knowledge on the Subject: The chitinases and related proteins have shown promise as novel circulating markers of inflammation in patients with respiratory disease.
What This Study Adds to the Field: We contribute knowledge to this field regarding factors that regulate levels of chitinases and related proteins in the blood. We conclude that these proteins are relatively steroidinsensitive, non-T-helper cell type 2-specific markers of chronic rather than acute disease processes.
Genotyping
The CHIT1 24-bp duplication (rs3831317) and 2131C.G polymorphism in the CHI3L1 gene (rs4950928) were genotyped as described in the online supplement. DNA was available from subjects taking part in the BIOAIR study (n=179), as well as from the healthy control subjects (n=58 for CHI3L1 and n=72 for CHIT1).
Statistics
Basic comparisons were performed using GraphPad Prism statistical software (GraphPad Software, La Jolla, CA), and P values ,0.05 were accepted as significant. The majority of variables in this study were not normally distributed according to the Kolmogorov-Smirnov test and therefore were analyzed using nonparametric tests. The results are presented as median (interquartile range) unless otherwise stated. Further analyses were performed using Stata 13 software (StataCorp, College Station, TX). Linear regression was used to adjust for age, sex, and genotype, and a linear mixed model was used for dependent samples (e.g., before vs. after treatment). For all regression analyses, logarithmic transformations of chitinase and YKL-40 measurements were performed before analysis. Fisher's exact test was used to examine genotype frequencies between groups. Multiple regression models were constructed to examine the effects of age, sex, genotype, smoking, disease, and lung function on chitinase levels. Some variables showed clear deviations from linearity, and these were fitted using cubic splines with three knots (23) .
Results

Baseline Serum YKL-40 Levels and Chitotriosidase Activity
The results are presented as median (interquartile range). Compared with serum YKL-40 levels in healthy control subjects (23.0 [17.1-26.5 ] ng/ml; n = 48), levels were significantly elevated in patients with mild to moderate asthma (33.3 [22.9-43.5 ] ng/ml; n = 61; P , 0.001) and those with severe asthma (43.3 [31.1-75.9 ] ng/ml; n = 76; P , 0.001) and were highest in patients with COPD (64.0 [37.4-142.2] ng/ml; n = 45; P , 0.001) ( Figure 1A ). All patient groups were significantly different compared with each other (mild to moderate asthma vs. severe asthma, P = 0.002; mild to moderate asthma vs. COPD, P , 0.001; severe asthma vs. COPD, P = 0.006).
Compared with healthy control subjects (62.5 [46.0-90 .0] nmol/ml/h; n = 72), serum chitotriosidase activity was greatest in patients with COPD (169.5 [90.0-269.6] nmol/ml/h; n = 52; P , 0.001) but was also significantly elevated in subjects with mild to moderate asthma (96.3 [61. 3-137.6 ] nmol/ml/h; n = 63; P , 0.001) and those with severe asthma (90.7 [58.1-134.8] nmol/ml/h; n = 84; P = 0.001) ( Figure 1B ). Chitotriosidase levels in both asthma groups were lower than those in patients with COPD (P , 0.001).
Effect of CHI3L1 rs4950928 and CHIT1 rs3831317 Genotype on YKL-40 Levels and Chitotriosidase Activity
The frequencies of the CHIT1 rs3831317 and CHI3L1 rs4950928 genotypes in the different subject groups are shown in Table 2 . The occurrence of the different genotypes was not different between the subject groups (P = 0.976 for CHI3L1 rs4950928 and P = 0.421 for CHIT1 rs3831317). YKL-40 levels were related to CHI3L1 rs4950928 genotype (Figure 2A ). When all subjects were analyzed together, those with the CC genotype showed higher levels of serum YKL-40 (39.0 [25.5-75.5] ng/ml; n = 120) than those with the CG genotype (32.2 [20.2-47.5] ng/ml; n = 54; P = 0.009) and those with the GG genotype, in whom levels were lowest (18.1 [11.5-28.3 ] ng/ml; n = 11; P , 0.001).
Following regression analyses with adjustment for CHI3L1 rs4950928 genotype, age, and sex, patients with mild and severe asthma and patients with COPD all still had significantly higher YKL-40 levels than healthy control subjects (P , 0.001). A significant difference also remained between patients with mild asthma and those with COPD (P = 0.018), but not between patients with mild asthma and those with severe asthma (P = 0.062) or between patients with severe asthma and those with COPD (P = 0.283).
Serum chitotriosidase activity showed a strong relationship with CHIT1 rs3831317 genotype ( Figure 2B ). Subjects homozygous for a 24-bp duplication in exon 10 were completely lacking in chitotriosidase activity, although this genotype was rare among subjects (2.3% in total) and therefore the data were too few to be included in statistical comparisons. Comparing all subjects, those lacking the 24-bp duplication had significantly greater levels of chitotriosidase than heterozygotes (respectively, 113.6 [74. 5-156.6 
When between-group differences in chitotriosidase activity were examined in regression analyses with adjustment for age, sex, and genotype, mild asthma and COPD were significantly different compared with healthy control subjects (P , 0.001), whereas severe asthma was not (P = 0.106). There were also significant differences in chitotriosidase activity between COPD and severe asthma (P = 0.007) and between mild and severe asthma (P = 0.051), but not between mild asthma and COPD (P = 0.416).
Overall, there were no associations between CHI3L1 rs4950928 or CHIT1 rs3831317 genotype and subject characteristics (see Tables E4 and E5 in the ; P = 0.034). However, it should also be noted that the present study is underpowered to examine clinical characteristics between different genotypes in the resulting subgroups.
Relationships between the Chitinases and Subject Characteristics
Possible correlations between levels of serum YKL-40 and chitotriosidase activity and subject characteristics were examined (Table 3) . In all BIOAIR patients, age was found to correlate positively with both YKL-40 (r = 0.49; P , 0.001) and chitotriosidase activity (r = 0.47; P , 0.001). Measures of lung function showed negative correlations with both YKL-40 levels (FEV 1 % predicted, r = 20.42, P , 0.0001; FVC % predicted, r = 20.40, P , 0.0001; FEV 1 /FVC, r = 20.34, P , 0.001) and chitotriosidase levels (FEV 1 , r = 20.25, P , 0.001; FVC, r = 20.16, P = 0.03; FEV 1 /FVC, r = 20.23, P = 0.001). In addition, there was a weak but statistically significant correlation between serum YKL-40 level and chitotriosidase activity (r = 0.221; P = 0.003). Correlations in the separate subject groups are shown in Tables E6 and E7 . YKL-40 also showed a weak though significant association with BMI, but only in patients with asthma (r = 0.21; P = 0.01).
Chitinase Levels in T-Helper Cell Type 2-driven Asthma
In patients with asthma, no significant correlations were observed between either YKL-40 level or chitotriosidase activity and proposed markers of T-helper cell type 2 (Th2)-type inflammation, including serum periostin, blood eosinophils, FE NO , and total IgE (Table E6) . To further examine possible relationships between chitinase levels and Th2-type inflammation, patients with asthma were divided into a Th2-high group, based on the presence of both blood eosinophil counts and periostin levels above the group median (median eosinophil count, 0.25 3 10 9 /L; median periostin level, 84 ng/ml), and a Th2-low group, in whom levels of both biomarkers were below the median (Table 4) . No differences in chitinase levels were observed between the Th2-low and Th2-high groups.
Effect of Steroid Treatment on Chitinase Levels
The effect of a 2-week, placebo-controlled oral steroid intervention was examined in subjects taking part in the BIOAIR study. No significant reductions in YKL-40 levels were observed following corticosteroid treatment ( Figure 3A) .
When the effect of steroid treatment was analyzed in all patient groups, serum chitotriosidase activity was slightly reduced following treatment with oral prednisolone (106 vs. 101 [63-143] nmol/ml/h; n = 157; P , 0.001). However, when patient groups were analyzed separately ( Figure 3B ), oral steroid treatment caused a reduction in chitotriosidase activity only in patients with COPD (186 [111-279] vs. 128 (86-189) nmol/ml/h; n = 38; P , 0.001). When interactions between treatment and age were taken into account, the interaction between treatment and subject groups ceased to be significant. The interaction between treatment and age in this model was negative (P = 0.001); that is, the reduction in chitotriosidase activity was greater in older people. There were no interactions between the examined genotypes and effect of corticosteroid therapy on chitinase levels.
In patients with asthma, neither baseline YKL-40 level nor chitotriosidase activity was associated with response to corticosteroid therapy, defined as an increase in FEV 1 greater than 12% following treatment with oral prednisolone. YKL-40 levels in nonresponders were 39 (26-69) ng/ml (n = 102) compared with 33 (25-53) ng/ml in responders (n = 22) (P = 0.276), whereas chitotriosidase activity was 94 (61-132) nmol/ml/h in nonresponders compared with 94 (60-158) nmol/ml/h in responders (P = 0.594).
Effect of Exacerbations on Chitinase Levels
Compared with baseline, neither YKL-40 level nor chitotriosidase activity was significantly different during exacerbations (Table E8 ). Exacerbations occurred in 7 patients with mild to moderate asthma, 27 patients with severe asthma, and 11 patients with COPD. Chitinase levels before and during exacerbations showed no significant interactions with age or genotype.
Repeatability of Chitinase Measurements
In the BIOAIR study, patients were followed for 1 year, during which time up to six blood samples were obtained at different time points (not during exacerbations). The data for average between-visit variability for YKL-40 levels and serum chitotriosidase activity, as well as the variability of FE NO and percentage of sputum eosinophils for comparison, are shown in Table 5 .
Chitinase Levels and Smoking Status
Of 76 patients with mild asthma, 1 was a current smoker and 14 were former smokers. Of 93 patients with severe asthma, 29 were former smokers and 2 were current ORIGINAL ARTICLE smokers. All 64 patients with COPD were either former (n = 45) or current (n = 19) smokers. We found no significant differences in either YKL-40 or chitotriosidase levels when we compared the patients with asthma who were never smokers with those who had smoked previously, nor did we find such differences when we compared patients with COPD who were former versus current smokers ( Figure E2 ). When univariate correlations were performed on the BIOAIR group as a whole, a significant relationship with number of pack-years smoked was observed (Table 3) , although this association was not apparent when the disease groups were analyzed separately (Tables E6 and E7 ).
Multiple Regression Analyses
As the findings above implied that YKL-40 levels and chitotriosidase activity are affected by several factors, we performed multiple regression analyses to examine the effects of the independent variables age, sex, genotype, smoking status, disease group, and lung function on chitinase levels. In the BIOAIR patient group as a whole, YKL-40 levels were significantly associated with, in descending order of importance, lung function (FVC % predicted), rs4950928 genotype, age, and sex (Tables 6 and 7) . FVC showed a nonlinear relationship with YKL-40 levels, as demonstrated in Figure E3 . For the whole patient group model, smoking (in packyears) and disease group were without significant effects. Multiple regression analyses in the separate groups are shown in Tables E9-E11 . Generally similar associations were observed when the groups were analyzed separately, although there was no effect of lung function in patients with mild asthma (Table E9) .
In descending order of importance in the BIOAIR group as a whole, genotype, age, and smoking status (in pack-years) were found to have significant effects on chitotriosidase activity. The difference between mild asthma and COPD was significant, but the difference between mild and severe asthma was not. No significant relationships with lung function were observed (Tables 6 and 7) . The relationship between chitotriosidase activity and number of pack-years of smoking was not linear, as shown in Figure E4 . When the patient groups were is shown in subjects with the rs4950928 2131 CC, CG, and GG genotypes. Information regarding CHI3L1 genotype and YKL-40 levels was available for 39 healthy control subjects and 49 subjects with mild to moderate asthma, 60 with severe asthma, and 37 with chronic obstructive pulmonary disease (COPD). Chitotriosidase activity is shown in subjects lacking a 24-bp analyzed separately (Tables E9-E11) , we found that the factors affecting chitotriosidase activity were age and genotype. A relationship with pack-years of smoking was observed only in patients with mild asthma, in whom it should be noted that the number of patients with a positive smoking history was also relatively low (15 of 76).
Effect of Allergen Challenge on YKL-40 Levels
The effects of high-dose and repeated low-dose allergen challenges on plasma and sputum YKL-40 levels were examined in patients with mild atopic asthma ( Figure 4 ). Plasma YKL-40 was not affected by either high-dose allergen challenge or repeated low-dose allergen challenge, although both challenges resulted in significant physiological responses (i.e., reductions in FEV 1 and increased responsiveness toward inhaled methacholine) (18, 19) . Sputum YKL-40 levels were significantly higher following high-dose allergen challenge (before challenge, 68 ng/g sputum; after challenge, 113
[69-258] ng/g sputum; n = 15; P = 0.007), but they were not affected by repeated low-dose allergen challenge. Sputum YKL-40 levels correlated with number of sputum neutrophils in both studies (r = 0.5; P , 0.05).
Discussion
The main findings of the present study are that serum YKL-40 levels and chitotriosidase activity are elevated in patients with asthma and in patients with COPD compared with healthy control subjects. Both YKL-40 and chitotriosidase were higher in subjects with COPD than in patients with mild to moderate asthma or those with severe asthma, and the increased levels correlated with reduced lung function and were relatively steroid insensitive. We demonstrate that genetic variability and age strongly affect both YKL-40 and chitotriosidase activity but that the increased levels compared with healthy control subjects mostly persisted after adjustment for these factors. Acute changes in airway inflammation caused by allergen exposure or naturally occurring exacerbations were without effect on the circulating chitinases measured, and the variability of serum YKL-40 and chitotriosidase activity over time was relatively low. Taken together, these findings confirm that the chitinases represent a distinct class of biomarkers of severe airway disease and provide important information regarding their use as such. Serum YKL-40 levels and chitotriosidase activity have not previously been examined in parallel in patients with COPD and patients with asthma. The finding of increased serum YKL-40 in patients with asthma confirms previous observations (7, 8, 24, 25) . The higher levels in patients with severe asthma than in patients with mild asthma, along with the correlation between YKL-40 and reduced lung function, strengthen the association of serum YKL-40 with disease severity (7, 8) . The exact biological role of YKL-40 remains unclear, but it consistently correlates with airway obstruction in studies of patients with asthma (7, 8, 24) . YKL-40 associates with measures of airway remodeling, such as bronchial wall thickness and subepithelial Figure 2 . (Continued). duplication in exon 10 of CHIT1 rs3831317 (wild type), those heterozygous for the 24-bp duplication, and those homozygous for the 24-bp duplication. Information regarding CHIT1 genotype and chitotriosidase activity were available from 64 healthy control subjects and 51 patients with mild to moderate asthma, 67 with severe asthma, and 44 with COPD. The results are presented as individual data points with median bars. *P , 0.05, **P , 0.01, ***P , 0.001. fibrosis (7, 8) , which is in line with reports that YKL-40 increases the proliferation of bronchial smooth muscle cells (26, 27) and is involved in fibrotic lung diseases (28) . Also of relevance to a role in airway remodeling is the discovery that a high serum YKL-40 level is associated with a greater decline in lung function over time (29) . The increased YKL-40 levels in patients with COPD compared with patients with asthma may therefore reflect a greater degree of airway remodeling.
It is widely recognized that asthma is a heterogeneous disorder of multiple phenotypes characterized by differing clinical characteristics and underlying pathobiology. Patients with Th2-driven asthma have been described as being more atopic and more sensitive to corticosteroid therapy and as having more airway eosinophils and a greater degree of bronchial hyperresponsiveness (30) . Blood eosinophils, FE NO , and serum periostin levels have been described as potential biomarkers of Th2-type airway inflammation (30) . In the present study, we did not observe any relationships between either YKL-40 or chitotriosidase with atopic status, response to corticosteroid therapy, blood eosinophil numbers, or serum periostin levels. Dividing patients into Th2-high and Th2-low groups based on having both high blood eosinophil and high periostin levels did not reveal any differences in chitinase levels.
In accordance with our findings, Jia and colleagues showed that whereas periostin may be the most sensitive and specific indicator of airway eosinophilia, there were no correlations between YKL-40 with periostin, eosinophils (in blood, sputum, or tissue), or FE NO (31) . Regarding atopy, the reported findings are variable. On one hand, Chupp and colleagues (7) and Ober and coworkers (12) reported no associations between YKL-40 with atopy or IgE. On the other hand, Tang and colleagues (24) found higher circulating YKL-40 levels in Chinese patients with higher IgE levels, and Specjalski and coworkers (32) made the same observation in patients with atopic versus nonatopic asthma. In the present study, we also observed the highest levels of YKL-40 and chitotriosidase in patients with COPD, further suggesting that the chitinases are not Th2-specific markers of airway disease. Interestingly, a weak association with increased BMI was observed, which has also been described previously (32) . In contrast to our findings, initial studies in mice did suggest an involvement in Th2-type processes, as the expression of chitinase proteins (AMCase, Ym1, and Ym2) is dependent on IL-13 (3, 33, 34) and mice lacking Brp39 (YKL-40) have defective IL-13-induced inflammation (35) .
Chitotriosidase activity was significantly elevated in patients with mild to moderate asthma compared with healthy control subjects, but not in patients with severe asthma, following adjustment for age, sex, and genotype. Published reports regarding chitotriosidase activity in asthma are few and varied, with differences based on the matrix studied, the severity of patients' disease, and/or patients' current medications. Studies have shown that, compared with healthy control subjects, there may be reduced chitotriosidase activity in bronchoalveolar lavage (BAL) fluid from patients with mild asthma not being treated with steroids (4), no difference in serum from patients with asthma (36) , and increased levels in the serum of patients with asthma with or without allergies (6) . The lack of association with disease severity, alongside conflicting previous findings, suggests that the involvement of chitotriosidase in asthma is less clear than that of YKL-40.
The increased YKL-40 and chitotriosidase seen in patients with COPD is in accordance with previous observations. Increased BAL chitotriosidase activity has been found in smokers (4, 5) , and elevated circulating YKL-40 has been found in patients with COPD compared with control subjects, in whom levels may relate to smoking history (37, 38) . In the present study, no differences were observed between current smokers and ex-smokers, suggesting that current smoke exposure per se is not responsible for increased chitinase levels. However, a significant relationship between chitotriosidase activity and packyears of smoking was observed in the multiple regression analyses, suggesting that the degree of airway damage may affect Definition of abbreviation: Th2 = T-helper cell type 2. Asthma patients were grouped according to having both serum periostin levels and blood eosinophil numbers above (Th2-high) or below (Th2-low) the group median (median eosinophil count, 0.25 3 10 9 /L; median periostin level, 84 ng/ml). Results are presented as median (interquartile range).
chitotriosidase activity. There may be involvement of airway neutrophils and macrophages, as these were more abundant in COPD sputum compared with asthma sputum. Both neutrophils and macrophages are known sources of YKL-40 and chitotriosidase (39) (40) (41) , although no obvious relationships were observed between airway neutrophils and macrophages and either YKL-40 or chitotriosidase in BIOAIR study patients. We and others have demonstrated that serum levels of both YKL-40 and chitotriosidase increase with age (42, 43) . The patient groups in the BIOAIR study were not age matched, but significant between-group differences remained following statistical adjustment for age, suggesting that age alone is not responsible for any of the observed increases in chitinase levels.
YKL-40 and chitotriosidase levels were both strongly affected by variations in the CHI3L1 and CHIT1 genes, respectively. Genetic variants in the CHI3L1 gene have been associated with asthma and related phenotypes (12, (44) (45) (46) . Ober and colleagues (12) observed a relationship between one particular CHI3L1 polymorphism (2131C.G rs4950928), circulating YKL-40 levels, and asthma. We confirm that the rs4950928 CC genotype was associated with greater levels of circulating YKL-40; in contrast to Ober and colleagues, however, we did not observe any associations with markers of asthma severity, which has also been the case in other recent investigations (46) . As DNA methylation can affect transcription factor binding, we investigated the effect of DNA methylation at three sites located in the CHI3L1 promoter region near rs4950928 because this single-nucleotide polymorphism affects MYC and MAX binding (12) . However, no clear trends were observed between DNA methylation in this region and circulating YKL-40 levels ( Figure E1 and Table E3 ). The CHIT1 24-bp duplication (rs3831317) results in a nonfunctional protein lacking enzymatic activity (13) . This genetic variant shows no association with asthma and atopy (47, 48) , and in the present study no differences in the frequencies of the CHIT1 rs3831317 variants were observed in the different disease groups.
The BIOAIR study included a 2-week, placebo-controlled steroid intervention with oral prednisolone. In patients with asthma, steroid treatment did not reduce serum YKL-40 or chitotriosidase activity. There was a reduction in serum chitotriosidase activity, but not of YKL-40, after steroid treatment in patients with COPD, those who were oldest, and those who had the highest levels of chitotriosidase activity. It should be noted, however, that subjects in the BIOAIR study used inhaled corticosteroids. That could potentially have affected basal chitinase levels, as Lai and colleagues recently showed that serum YKL-40 was reduced following 8 weeks of inhaled corticosteroid treatment (49) . Nevertheless, as we and others have shown, patients taking the highest doses of ICS are also those with the highest levels of YKL-40, suggesting that YKL-40 release is relatively refractory to steroid treatment (7, 49) . One may speculate that the reason why chitinase levels are highest in patients with the most severe disease and taking the highest levels of corticosteroids is that corticosteroids are able to alternatively activate macrophages, a cell type known to release mediators involved in tissue repair (50) .
To investigate the repeatability of chitinase measurements, up to six serum samples were collected from the same patients over a 1-year period. The mean coefficients of variation were 16-19% for chitotriosidase and 32-38% for YKL-40. In comparison with other biomarkers measured at the same time points, such as FE NO (coefficient of variation, 45-56%) and sputum eosinophil percentage (coefficient ORIGINAL ARTICLE of variation, 91-95%), both chitotriosidase and YKL-40 were relatively stable. Naturally occurring exacerbations, most commonly caused by viral infections, in patients with severe asthma and patients with COPD were without effect on the levels of the chitinases measured, suggesting that they do not reflect acute changes in airway inflammation.
In the present study, circulating YKL-40 remained unchanged following high-dose allergen challenge or repeated low-dose allergen challenge. Sputum YKL-40 was increased by a high-dose allergen challenge. Lee and colleagues also showed that sputum, but not serum, YKL-40 levels increased at 7 and 24 hours after a single highdose allergen challenge (51) . Similarly, Gavala and colleagues found that BAL fluid YKL-40 levels were increased 48 hours after in vivo segmental high-dose allergen challenge (52) . Taken together, these data seem to show that sputum (and BAL) may reflect a local release of YKL-40 during allergen-induced inflammation that is not reflected in the blood. A single high dose of allergen may be considered a greater challenge for the airways than repeated low doses, and, as the latter is considered a more realistic model of natural allergen exposure, YKL-40 levels may remain relatively stable during such exposures in everyday life. In both studies, sputum YKL-40 correlated with neutrophil numbers, confirming previous reports of the cellular origin of YKL-40 (41) .
As the BIOAIR study was designed to compare severe asthma and COPD with mild asthma, the study cohort lacks an internal healthy control group, which is a limitation. To compare chitinase levels with those in healthy subjects, we used a previously described control group (17) . However, clinical characteristics of relevance to respiratory disease were not available for these control subjects, thus preventing their inclusion in multiple regression analyses. Nevertheless, performing such analyses for the groups with respiratory disease only was able to further highlight the importance of age, genotype, lung function, and sex on YKL-40 levels and similarly the effects of age, genotype, and smoking history on chitotriosidase activity.
In conclusion, we demonstrate that YKL-40 and chitotriosidase are relatively steroidinsensitive biomarkers that are distinctly elevated in well-characterized patients with asthma and patients with COPD. Taking into account age and genetic variability, the chitinases qualify for measurement as part of new biomarker panels for the assessment of severe, chronic lung inflammation rather than acute lung inflammation. Furthermore, it will be of interest in future longitudinal studies to test the prognostic value of monitoring chitinases as biomarkers of decline in lung function (29) , be it in patients with asthma, COPD, fibrosis, or infections or in pediatric conditions such as bronchopulmonary dysplasia. n . Plasma and sputum levels of YKL-40 following high-dose and repeated low-dose allergen challenges. Plasma levels of YKL-40 were measured (A) before, directly after, and 7 hours after highdose allergen challenge (n = 16) and (B) before and after a 7-day repeated low-dose allergen challenge (n = 14). No significant differences were observed. Sputum supernatant levels of YKL-40 were measured (C) before and 6 hours after high-dose allergen challenge (n = 15) and (D) before and after a 7-day repeated low-dose allergen challenge (n = 11). The results are expressed as nanograms of YKL-40 per gram of processed sputum. High-dose allergen challenge significantly increased sputum YKL-40 (P = 0.018), but low-dose allergen challenge was without effect. 
